IGF-1 LR3 Research: Concentration-Response and Myocyte Cell Model Studies
IGF-1 LR3 Concentration-Response Strategies for Myocyte Signalling Pathway: A Research Perspective
IGF-1 LR3 is a research compound studied in cell-based assay formats for its IGF-1R tyrosine kinase receptor IRS-1/PI3K/AKT/mTOR pathway activation. Published in vitro research characterizes its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
Receptor Pharmacology and Mechanism of Action
IGF-1 LR3 acts via IGF-1R tyrosine kinase receptor IRS-1/PI3K/AKT/mTOR pathway activation. Competitive binding studies demonstrate high affinity interactions with the IGF-1 receptor, exhibiting enhanced potency compared to native IGF-1 in cellular assays. The compound's structural modifications, particularly the N-terminal extension and amino acid substitution at position 3, confer resistance to IGF binding protein interference and extend biological half-life in cell culture medium.
IGF-1 Receptor Binding Characteristics
Radioligand binding assays reveal IGF-1 LR3 maintains nanomolar affinity for the IGF-1 receptor while displaying reduced affinity for insulin receptors. Scatchard plot analyses indicate specific, saturable binding with Kd values typically ranging from 0.1-1.0 nM in various cell line models. Competition binding studies using [125I]-IGF-1 demonstrate IC50 values consistent with high-affinity receptor occupancy.
Downstream Signalling Cascade Activation
Upon receptor binding, IGF-1 LR3 initiates autophosphorylation of the IGF-1 receptor β-subunit tyrosine kinase domain. This phosphorylation event creates docking sites for insulin receptor substrate-1 (IRS-1), leading to subsequent phosphorylation of IRS-1 tyrosine residues. Activated IRS-1 recruits and activates phosphoinositide 3-kinase (PI3K), resulting in phosphatidylinositol 3,4,5-trisphosphate (PIP3) generation at the plasma membrane.
In Vitro Cell Model Systems
Myocyte Cell Culture Models
Primary myocyte cultures and established myoblast cell lines serve as standard experimental models for IGF-1 LR3 receptor pharmacology studies. C2C12 myoblast cells differentiated into myotubes provide a reproducible system for examining concentration-response relationships and temporal signalling dynamics. L6 skeletal muscle cells offer an alternative model system with well-characterized IGF-1 receptor expression profiles.
Concentration-Response Characterization
Dose-response studies typically employ logarithmic concentration series ranging from 1 pM to 1 μM IGF-1 LR3. EC50 values for various downstream endpoints, including AKT phosphorylation, mTOR activation, and protein synthesis markers, consistently fall within the 0.1-10 nM range across multiple cell model systems. Hill coefficients approaching unity suggest simple receptor occupancy kinetics without apparent cooperativity.
Signalling Pathway Analysis Methods
Phosphoprotein Detection Assays
Western blot analysis utilizing phospho-specific antibodies enables quantitative assessment of key signalling intermediates. AKT phosphorylation at Ser473 and Thr308 serves as a primary readout for PI3K pathway activation. mTOR phosphorylation at Ser2448 indicates downstream target engagement, while S6K1 and 4E-BP1 phosphorylation reflects mTORC1 complex activity.
Kinetic Enzyme Activity Measurements
Real-time monitoring of receptor tyrosine kinase activity employs fluorescence-based assay platforms. These systems enable measurement of phosphorylation kinetics with temporal resolution sufficient to characterize initial rate parameters and maximum velocity (Vmax) values. Michaelis-Menten kinetic analysis provides Km determinations for substrate phosphorylation reactions.
Binding Protein Interactions
IGFBP Resistance Properties
IGF-1 LR3's structural modifications confer reduced affinity for insulin-like growth factor binding proteins (IGFBPs). In vitro binding competition assays demonstrate significantly diminished interaction with IGFBP-3, the most abundant binding protein in serum-containing media. This property enhances bioavailability in cell culture systems containing serum or purified binding proteins.
Stability and Degradation Kinetics
Proteolytic stability assays reveal extended half-life compared to native IGF-1 in conditioned cell culture medium. The N-terminal extension provides protection from aminopeptidase activity, while the amino acid substitution reduces susceptibility to specific endopeptidase cleavage. Time-course studies demonstrate sustained receptor activation over extended incubation periods.
Research Summary
IGF-1 LR3 represents a valuable research tool for investigating IGF-1 receptor-mediated signalling pathways in myocyte cell model systems. Its enhanced binding protein resistance and extended stability enable controlled concentration-response studies with reduced experimental variability. The compound's high-affinity receptor binding and robust downstream pathway activation make it suitable for mechanistic studies examining IRS-1/PI3K/AKT/mTOR signalling cascade components. Cell-based assay formats utilizing myoblast and myocyte cultures provide reproducible experimental systems for characterizing receptor pharmacology parameters and signalling kinetics. These in vitro approaches facilitate detailed analysis of molecular mechanisms underlying IGF-1 receptor activation and downstream cellular responses in defined laboratory conditions.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML